Abstract
Get full access to this article
View all access options for this article.
References
1.Eli Lilly . Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting . 2024 . Available from: https://investor.lilly.com/news-releases/news-release-details/positive-phase-12-clinical-trial-data-investigational-gene [Last accessed:
February 12 , 2024
].
2.Vertex Pharmaceuticals . European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia . 2024 . Available from: https://investors.vrtx.com/news-releases/news-release-details/european-commission-approves-first-crisprcas9-gene-edited [Last accessed:
February 13 , 2024
].
3.Fractyl Health . Form 424B4, Initial Public Offering Prospectus . 2024 . Available from: https://ir.fractyl.com/static-files/e5b27d68-11d3-473b-8340-5f495b039dfe [Last accessed
February 13 , 2024
].
4.Bayer and Asklepios BioPharmaceutical . First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure . 2024 . Available from: https://www.askbio.com/first-patient-randomized-in-askbio-phase-ii-gene-therapy-trial-for-congestive-heart-failure/ [Last accessed:
February 13 , 2024
].
5.Ultragenyx Pharmaceutical . Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) . 2024 . Available from: https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-data-demonstrating-treatment-ux111-results [Last accessed:
February 14 , 2024
].
6.Sensorion . Sensorion Announces a €50.5 Million Financing with Participation From New and Existing US and European Healthcare Specialist Investors. February 9, 2024. Available from: https://s27.q4cdn.com/232015521/files/doc_news/Sensorion-Announces-a-50.5-Million-Financing-With-Participation-From-New-and-Existing-US-and-European-Healthcare-Specialist-Investors-2024.pdf [Last accessed:
February 13 , 2024
].
7.Sangamo Therapeutics . Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease . February 12, 2024. Available from: https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-us-fda-alignment-abbreviated [Last accessed:
February 13 , 2024
].